Market Signal Briefing

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Moonlake Immunotherapeutics saw its shares plummet over 80% on Monday October 13, 2025 after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients’ baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.

To learn more about the Tvardi investigation, go to www.faruqilaw.com/TVRD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Analyst’s Disclosure:I/we have a beneficial long position in the shares of WES either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Opendoor has outperformed the S&P 500 recently, but this could soon change in a big way.

Recently, Opendoor Technologies (OPEN 1.16%) has become one of the top meme stocks, leading to big gains for investors over the past year. Relative to three years ago, the stock is also up substantially.

However, over the past five years, shares in iBuyer have experienced a high level of underperformance, losing considerable value. In contrast, the S&P 500 has nearly doubled during the same time frame.

Investors should keep this in mind before holding onto or entering a new position in this name. While still propped up by "meme mania" for now, other factors could soon send shares back toward prior lows.

Image source: Getty Images.

Opendoor versus the S&P 500
As seen in the table below, Opendoor's investment returns relative to the S&P 500 appear extremely strong over a one-year and three-year time frame, but not so much over a five-year time frame.

Timeframe

Opendoor Return

S&P 500 Return

1 Year

286.43%

12.33%

3 Years

271.5%

66.5%

5 Years

(62.4%)

84.73%

Even if you have just a vague understanding of Opendoor's historical price performance, you likely know the reason why this stock has experienced outsize gains in the past three years, but has severely lagged the market over the past five years.

Going public via a special purpose acquisition company (SPAC) merger in 2020, Opendoor shares initially surged. At the time, Opendoor was scaling up at a rapid clip, a trend expected at the time to carry on in the years ahead.

However, starting in 2021, the company and its shares experienced the double-whammy of a housing market slowdown, coupled with macroeconomic changes that led to a big retreat from speculative growth stocks. As a result, shares cratered from the mid-$30s to the low single digits per share.

This pullback carried on into 2023, 2024, and even into 2025, as a sluggish housing market led to continued revenue declines and heavy net losses for the company. However, thanks to the "meme mania" surrounding the stock starting last summer, shares have entered a new period of market outperformance.

Today's Change

(

-1.16

%) $

-0.09

Current Price

$

7.69

Why this big comeback may prove fleeting
In short, while Opendoor's meme stock rally has resulted in shares climbing past lows hit during recent years, the stock has yet to return to price levels last hit in the months following its stock market debut.

Meme-related bullishness has calmed down as of late, but many speculators still believe further upside may be in the cards. After all, with the stock's high short interest, it may not take much to trigger another short squeeze. Then again, maybe not.

Sure, Opendoor's management has touted that a just-completed distribution of tradable stock warrants to shareholders could help drive another short squeeze. However, as I recently argued, another recent corporate action could counter this squeeze potential: the redemption of convertible bonds in exchange for stock.

This has led to share dilution, which could put pressure on shares if the company's financials don't soon improve. Despite recent turnaround talk, sell-side analysts still expect Opendoor to report heavy losses in 2025 and 2026. Hence, while "meme mania" has enabled the stock to bounce back from recent lows, a reversal may be just around the corner.

Both of these stocks have underperformed in 2025. But they could crush the market in 2026 and beyond.

After a big run-up in many tech stocks this year, many of Wall Street's darlings now trade at stretched valuations. But not all of Wall Street's most popular tech stocks have fully participated in this year's rally. Surprisingly, several names in the "Magnificent Seven" have underperformed the Nasdaq Composite's sharp gains -- and two look particularly attractive: Apple (AAPL +0.46%) and Amazon (AMZN +1.77%)

The iPhone maker has just closed its fiscal 2025 with fourth-quarter revenue rising 8% year over year and earnings growing by double digits, helped by a record services performance. Meanwhile, the e-commerce and cloud computing specialist reported 13% revenue growth in the third quarter of 2025, with Amazon Web Services returning to 20% growth as AI (artificial intelligence) demand accelerates.

Among the Magnificent Seven, Apple and Amazon arguably stand out as the most attractive duo. And unlike some of the AI beneficiaries that have received so much attention this year, these are high-quality growth stocks rather than speculative bets.

Image source: Getty images.

1. Apple's durable ecosystem
Helping fuel its 13% year-over-year increase in earnings per share, Apple's services revenue climbed 15% to $28.8 billion in its most recent quarter. Further, this important segment boasts a gross profit margin above 75% -- far greater than its hardware gross margin. That high-margin services stream helps smooth out hardware cycles and turns each iPhone, Mac, or iPad in use into an annuity-like source of revenue for Apple.

To this end, management continues to emphasize the importance of Apple's installed base of active devices, which Apple said achieved an all-time high "across all product categories and geographic segments," in fiscal Q4.

As of the last time the company disclosed its total count of active devices, there were 2.35 billion. That kind of scale gives Apple a wide foundation for rolling out new services and AI features without relying on blockbuster new device categories every year.

Today's Change

(

0.46

%) $

1.27

Current Price

$

278.82

Management expects total revenue to grow 10% to 12% year over year in the important holiday quarter, with iPhone revenue returning to double-digit growth, suggesting that the iPhone 17 cycle and early AI features are providing momentum heading into 2026.

Of course, shares aren't cheap. Apple stock currently trades at roughly 37 times earnings -- comfortably above the S&P 500's price-to-earnings ratio in the mid-20s.

But given Apple's momentum in services and the company's loyal customer base, I think this stock is worth its premium price.

2. Amazon's profit expansion
Amazon's most recent quarter once again demonstrated the diversified nature of its business, with strong growth in e-commerce, advertising, and Amazon Web Services (AWS).

But AWS, in particular, is worth calling out.

"AWS is growing at a pace we haven't seen since 2022, reaccelerating to 20.2% [year over year]," said Amazon CEO Andy Jassy in the company's third-quarter update. "We continue to see strong demand in AI and core infrastructure, and we've been focused on accelerating capacity -- adding more than 3.8 gigawatts in the past 12 months."

Today's Change

(

1.77

%) $

4.06

Current Price

$

233.22

Operating income for the quarter held at $17.4 billion (the same as it was in the year-ago period), but that figure absorbed a $2.5 billion Federal Trade Commission settlement and $1.8 billion in severance costs. Excluding those items, operating income would have been $21.7 billion, implying a double-digit operating margin on the quarter's sales and highlighting how much leverage Amazon can generate from its fulfillment network, advertising, and cloud operations. This is also impressive in light of how heavily the company is investing in AI.

Speaking of AI, it's turning into a major catalyst for the company.

"We continue to see strong momentum and growth across Amazon as AI drives meaningful improvements in every corner of our business," CEO Andy Jassy said in the third-quarter earnings release.

Despite a reacceleration in AWS and management's optimism about AI's impact on its business, Amazon's valuation remains quite attractive. The stock trades at about 32 times earnings -- only modestly above the broader market despite double-digit revenue growth and a cloud business that is reaccelerating.

Apple and Amazon: Top picks for 2026 and beyond
Taken together, Apple and Amazon give investors two different but complementary ways to own the Magnificent Seven theme. Apple offers a massive installed base and high-margin services on top of a loyal customer base and a proven track record. But investors have to pay a premium valuation. Amazon offers more direct exposure to AI infrastructure, along with the rest of its diversified business, but trades at a lower valuation.

Both stocks carry risks, chief among them being valuation risk since neither stock is exactly cheap. Yet for forward-looking investors who want concentrated exposure to dominant U.S. tech franchises without venturing into the most speculative corners of the market, these two look like good options for 2026.

Is Fluor stock your best bet to profit from the nuclear renaissance? It certainly looks cheap enough.

If you want to invest in nuclear power stocks, I've got just one name for you: Fluor Corporation (FLR +1.23%).

Not Nano Nuclear Energy . Not NuScale Power Corporation (SMR +5.04%). Not Oklo -- none of the "SMR" start-up companies developing small modular nuclear reactors. None of them are profitable. According to forecasts from S&P Global Market Intelligence, none of them will be profitable for at least five more years -- and who knows what might happen between now and then.

And no, not Cameco Corporation or Denison Mines either. Even though the uranium mining companies are making money, they're not making enough money to justify their valuation. 

But Fluor Corporation is.

Image source: Getty Images.

Why you should seriously consider investing in Fluor stock
Fluor Corporation is different. Profitable in each of its last three years, Fluor has earned more than $1.5 billion already this year and appears on course to easily top analyst forecasts for $1.6 billion in 2025 profit.

The company's business is growing, with revenue from urban solutions (engineering and construction work on advanced manufacturing, life sciences, and mining projects) increasing by 42% over the past three years, and revenue from energy solutions (primarily oil and gas projects, as well as renewable energy and nuclear) up 20%. This has offset declines elsewhere in the business, allowing for 15% growth in total revenue.

And the company's nuclear business looks especially well positioned for growth.

In addition to Fluor's involvement in SMR projects, both through its ownership stake in NuScale and otherwise, Fluor has a history of involvement in the engineering and construction of larger-scale nuclear power plants. Over a period of decades, Fluor has designed and built three nuclear power units, built another eight nuclear power units as a contractor, and "supported construction" on 10 more -- in addition to performing maintenance and upgrades work on about 90 separate 90 nuclear reactor units.

It's very likely to play a major role in the nascent nuclear renaissance in the United States.

Big plans for Big Nuclear
In May 2025, President Trump signed four executive orders promoting American nuclear power as a means of boosting energy supplies to power artificial intelligence data centers. The president's interest in advanced nuclear technology, such as SMR reactors, is clear from the text of these orders. But lately, it's become just as clear that he's also interested in larger nuclear plants.

Earlier this week, for example, The Wall Street Journal reported the White House is encouraging Japan to commit $80 billion to build eight new big nuclear reactors, as part of that nation's deal to invest $550 billion in the U.S. in exchange for winning lower tariff rates on imports to the United States.

Initial reports suggest that this investment will take the form of four sets of paired nuclear reactors at four separate sites, each capable of generating 1,100 megawatts of nuclear power, and each costing approximately $10 billion to build, excluding financing costs. Westinghouse would design and build the plants based on its AP1000 nuclear power plant design. Still, Fluor might serve as the engineering and construction contractor on the projects, given its experience in building prior AP1000 reactors in the U.S.

Or if the AP1000 is not chosen as the basis for the new nuclear power plants, Fluor might serve as a contractor on other companies' projects, based on other designs.

Today's Change

(

1.23

%) $

0.52

Current Price

$

42.93

Valuing Fluor Corporation stock
Valuing Fluor stock is a little tricky. The company's market capitalization is $6.8 billion, but $1.8 billion of that is backed up by net cash on the balance sheet, reducing Fluor's enterprise value to $5 billion. Furthermore, Fluor owns a 38.9% stake in NuScale, currently worth about $2.2 billion -- arguably lowering Fluor's enterprise value even further, to $2.8 billion.

While calculating Fluor's real price tag, though, is tricky, it's relatively easy to determine that Fluor is an inexpensive stock.

Analysts expect Fluor to earn $360 million in net profit next year, for example, and generate $390 million in free cash flow. Depending on which figure you use, therefore, Fluor stock has an enterprise value of only 7.8 times forward earnings, or 7.2 times forward FCF. Both of these values appear inexpensive to me, relative to the 12% rate of earnings growth that analysts project for Fluor over the next three years.

When compared to the money-losing SMR nuclear start-ups in particular, all of which are expected to still be losing money three years from now, Fluor stock seems a much better bet to me.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC probe is revealed.

If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

Why are Jefferies and Point Bonita being Investigated?

Jefferies is an investment banking and capital markets firm. Its trade finance arm is named Point Bonita Capital. Jefferies and Point Bonita were two of the closest banking and financing partners of First Brands Group, LLC, an auto parts supplier which collapsed into bankruptcy in September 2025.

On October 8, 2025, Jefferies announced that it and Point Bonita had approximately $715 million in exposure to First Brands’ receivables, which represents roughly 25% of Point Bonita’s trade finance portfolio. On this news, the price of Jefferies stock fell $4.66 per share, or about 8%, from $59.10 per share on October 7, 2025, to $54.44 per share on October 8, 2025. Investors are reportedly currently seeking redemptions from Point Bonita as well.

On November 27, 2025, it was reported that the SEC is seeking information about whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to the auto business, which filed for bankruptcy in September with $12bn in debt. It was also reported that the SEC is also looking into internal controls and potential conflicts within and between different parts of the bank.

BFA is currently investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors in connection with this significant exposure to First Brands and the subsequent SEC probe into the company.

Click here for more information: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

What Can You Do?

If you invested in Jefferies or Point Bonita you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

SummaryEOG Resources (EOG) maintains a Buy rating, supported by strong financials, robust free cash flow, and a diversified multi-basin and international growth strategy.
EOG's integration of Encino, cost reductions, and international expansion drive higher FCF guidance, with 89% of 2025's estimated FCF already allocated to shareholder returns via dividends and buybacks.
Macro factors - including potential Fed rate cuts, geopolitical tensions, and OPEC actions - create both risks and opportunities for EOG, but natural gas exposure offers long-term potential.
Valuation analysis suggests an intrinsic value well above the current level, with EOG positioned for long-term growth despite near-term oil price volatility and macroeconomic uncertainties.
Maksim Safaniuk/iStock via Getty Images

Introduction Last time I covered EOG Resources (EOG), I highlighted their strong margins, robust cash flows, and very solid financials, with a multi-basin US strategy with an international expansion with natural gas on top.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in EOG, over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

LAS VEGAS, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Expanse Studios, an online casino content developer and a subsidiary of Golden Matrix Group, Inc. (NASDAQ: GMGI), Expanse Studios, a next-generation B2B iGaming content provider and subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), today announced a new strategic content distribution agreement with MerkurXtip, Southeast European-based gaming operator and member of the globally recognized Merkur Group (formerly Gauselmann Group).

The agreement marks a new chapter in Expanse Studios’ expansion across regulated European markets and strengthens GMGI’s broader B2B strategy. It will see Expanse’s most successful titles—Super Heli, Titan Roulette, Wild Icy Fruits, 100 Super Icy and others—integrated into MerkurXtip’s online and land-based network through Bragg Gaming aggregation platform.

This partnership marks another milestone in Expanse Studios’ ongoing European expansion strategy and reflects Golden Matrix Group’s broader vision of scaling its high-margin B2B operations. The expansion across highly regulated European markets demonstrates Expanse's dedication to providing engaging, region-specific gaming content via strong distribution partnerships.

“MerkurXtip is a respected and innovative operator in the European gaming ecosystem. This deal confirms the rising demand for our high-performing, localized content, and we’re proud to expand our reach with such a strong partner. Our focus remains on driving growth through quality content and scalable B2B distribution models,” said Damjan Stamenkovic, CEO of Expanse Studios.

Nenad Aleksić, Head of Online at MerkurXtip, added: “We’re committed to offering the best content to our players, both online and in retail. Expanse Studios brings fresh and dynamic games that align with our vision of constant innovation. We expect this collaboration to deliver exceptional added value on both ends.”

About Expanse Studios

Expanse Studios, part of the Golden Matrix Group (NASDAQ: GMGI), is a B2B iGaming content provider specializing in slots, crash games, turn-based strategies, and card games. With a growing portfolio of 56 proprietary titles, Expanse powers over 1,300 casino brands across Europe, LATAM, and North America. The studio distributes content for real-money gaming, alternative casino formats, and social platforms.

Learn more at expanse.studio.

About Merkur XTip

MerkurXtip is a regulated gaming and betting operator offering both online and retail services, with a network of over 100 shops throughout Southeast European markets. The company is part of the internationally recognized Merkur Group (formerly Gauselmann Group), a long-standing leader in the development and distribution of games, entertainment systems, and gaming technology.

About Golden Matrix

Golden Matrix Group (NASDAQ: GMGI), based in Las Vegas, is a gaming technology company operating globally through B2B divisions (GMAG, Expanse Studios) that develop and license proprietary platforms, and B2C operations including RKings (UK competitions), Mexplay (Mexico online casino), and Meridianbet—a leading sportsbook licensed in 18 jurisdictions across Europe, Africa, and South America. Learn more at www.goldenmatrix.com.

Contact: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/01c09e2e-ea4f-4929-a9e8-617c0a62abb1

Expanse x Merkur XTip
Expanse x Merkur XTip

Shares of Coca-Cola ( NYSE:KO ) gained 4.03% over the past month after gaining 4.10% the month prior.

The stock has lagged broader equities this year, but patient investors who initiate positions today might be very well rewarded in a decade.

Over the past 25 years, Intuitive Surgical (ISRG 0.13%) has experienced significant success thanks to its pioneering use of robotics in surgery. The healthcare leader now stands as the undisputed top player in the robotic-assisted surgery (RAS) market. However, things are changing, and Intuitive Surgical may face increased competition in the coming years that could disrupt its prospects.

Can the company maintain its leadership position while still delivering strong results and market-beating returns? Let's see how things might evolve for Intuitive Surgical over the next decade.

The first of several potential newcomers
Intuitive Surgical's da Vinci system is the company's best-known device. It has been approved across a range of procedures, and in many of them, it has little to no competition. But some healthcare giants are quickly looking to shake things up.

Image source: Getty Images.

First up, we have Medtronic, a medical device specialist. Medtronic completed clinical trials for its Hugo system in urologic procedures in the U.S. earlier this year. It is now awaiting regulatory clearance in that indication. And since announcing that win, Medtronic has also posted positive clinical trial results for the Hugo system in hernia repairs. The da Vinci system is approved for both urologic procedures and hernia repairs, so the two are heading straight for a collision.

Further, Medtronic is likely to seek additional indications that overlap with the da Vinci system. Meanwhile, another healthcare leader, Johnson & Johnson, is also developing an RAS system called Ottava. The device is currently in clinical trials for gastric bypass -- another one of the da Vinci system's indications -- in the U.S. It might be a few years before the Ottava hits the market, but it will add to Intuitive Surgical's competitive pressure.

Intuitive Surgical's advantages
Several factors could enable Intuitive Surgical to maintain its leadership position in the market. Let's consider two. First, its device not only has completed clinical trials and earned approvals across many indications, but it has also been in use in the real world for a long time. This first-mover advantage should give Intuitive Surgical an edge over newcomers in the field.

It has also allowed the company to get valuable feedback from healthcare professionals and modify its device as needed. The da Vinci system's fifth generation was launched just last year, with smashing success.

Today's Change

(

-0.13

%) $

-0.75

Current Price

$

573.48

Second, Intuitive Surgical already has a large installed base. It ended the third quarter with 10,763 installed da Vinci systems, representing a 13% year-over-year increase. Most of these are likely to remain in place. Not only is the device expensive, but it also requires a learning curve for surgeons to master. Switching to a competitor after putting in all that money, time, and effort is too much work for most healthcare facilities. Intuitive Surgical's switching costs are a powerful reason it should remain a leader.

It also allows for a recurring source of revenue. The instruments and accessories it sells for procedures have a short lifespan and need to be replaced regularly. And as procedure volume grows, so does the volume of accessories it sells.

Why Intuitive Surgical can still beat the market
Competition will intensify over the next decade, but robot-assisted procedures also should. One reason is that the market is severely underpenetrated. More players could help grow awareness, increase demand for the minimally invasive procedures they facilitate, and prompt even more hospital systems to invest in these devices.

Furthermore, the world's population is aging. By 2035, projections indicate that adults aged 65 and older will outnumber minors aged 18 and younger in the U.S. for the first time. This demographic shift will have significant implications for healthcare spending, as the elderly require more medical care, including the types of procedures that Intuitive Surgical offers with its da Vinci system. These tailwinds should help boost the company's procedure volume.

Intuitive Surgical has long generated steady revenue and earnings growth. It is still at it. And investors can expect much of the same over the next decade. The company could still deliver superior returns to patient investors.

SummaryNEOS Enhanced Income Credit Select ETF offers high-yield income by investing in high-yield bond ETFs and writing SPX put spreads.HYBI currently yields 8-9% with monthly distributions, but its portfolio leans toward riskier, below-investment-grade bonds.The fund's expense ratio is capped at 0.68%, and its performance is closely tied to the health of high-yield credit markets.Given the risk profile and lack of strong capital gain drivers, HYBI is rated as an adequate hold for income-focused investors. SSG PHOTO/iStock via Getty Images

NEOS Enhanced Income Credit Select ETF (HYBI) offers a balance between "junk" bonds and options writing for income. With a year on its belt, it's not done badly, but it also seems like it could disappoint under duress, for which

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

These funds offer yields that are more than three times the S&P 500 average.

Investing in the stock market today can be worrisome given how high valuations have become of late. That can add risk to your portfolio, and potentially make you vulnerable in the event of a correction -- or worse, a full-blown crash.

If you're in retirement and just want some steady, dependable income, the good news is that there are many reliable exchange-traded funds (ETFs) that can keep your risk low while providing solid returns. While the S&P 500 averages a yield of only 1.2%, there are ETFs that can give you much more in dividend income.

A couple of solid, dividend-focused ETFs you may want to consider today are the Vanguard International High Dividend Yield ETF (VYMI +0.26%) and the Schwab U.S. Dividend Equity ETF (SCHD +0.51%). Here's why these funds can be excellent options for your portfolio if your priority is dividend income.

Image source: Getty Images.

Vanguard International High Dividend Yield ETF
The Vanguard International High Dividend Yield ETF pays a fairly high yield of around 4%, which is easily more than three times the S&P 500 average. Meanwhile, it charges a low expense ratio of 0.17%.

This can be an attractive income investment if you're worried about the U.S. economy because it focuses on other markets. European stocks account for 43% of the ETF's holdings, followed by the Pacific region at 26%, and emerging markets make up another 22%. Overall, there are more than 1,500 stocks in this fund.

Another great feature about this ETF is how modest its holdings are -- no stock accounts for more than 2% of the overall portfolio. HSBC Holdings, Nestlé, and Novartis are currently its top three stocks, but together, they make up just 4.5% of the ETF's total holdings. That's great from a risk standpoint since it ensures that you aren't dependent on how just a few stocks perform, which is a big risk with many tech-heavy ETFs these days.

Today's Change

(

0.26

%) $

0.23

Current Price

$

87.72

The Vanguard fund has also averaged a beta of 0.92 over the past five years, which indicates that it is less volatile than the overall stock market. That doesn't mean that it won't struggle in a downturn, but it can be less volatile overall, which can be key if you just want to focus on dividend income.

Schwab U.S. Dividend Equity ETF
This is another top dividend ETF. As its name suggests, it focuses on U.S. dividend stocks. Together with the Vanguard fund, you can have a portfolio that encompasses both U.S. and international markets with just two investments.

The Schwab fund is much smaller in scope, with around 100 stocks in its portfolio. That can be a good thing with dividend stocks because it suggests a more carefully selected portfolio. The ETF's focus is on keeping costs low while targeting stocks that have strong financials and can sustain their dividend payments; it's not simply a huge collection of dividend-paying investments.

In this ETF, you'll find some top names when it comes to dividends, including Coca-Cola, AbbVie, and Cisco Systems. Those are among its top holdings. While there is a bit more exposure to individual stocks with this ETF, given its focus on quality dividend stocks, that doesn't take away from the overall safety with this fund.

Today's Change

(

0.51

%) $

0.14

Current Price

$

27.59

The Schwab ETF yields 3.8%, and its expense ratio of 0.06% is incredibly light. Meanwhile, its beta of 0.79 suggests it's an even less volatile investment than the Vanguard fund.

Although the ETF is down 1% this year, it has generated returns of around 30% in five years, and that's without including its dividend. Overall, it's a solid option for the long haul that can generate recurring income for the foreseeable future.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CLSK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Since 2023, these stocks have soared between 490% and 2,400%.

Generating a 50% return in one year is impressive. Doing it twice is amazing, and it might have you thinking that the stock is due for a letdown. But the stocks listed here are all on track to generate 50% returns for a third consecutive year in 2025.

Robinhood Markets (HOOD +0.23%), Palantir Technologies (PLTR +1.62%), and Sofi Technologies (SOFI +4.32%) have been among the hottest growth stocks to own since 2023. Here's a look at what's been behind their stellar gains in recent years, and if they still have more room to rise higher.

Image source: Getty Images.

Robinhood Markets
In 2023, Robinhood's stock rose by 57%, and then 193% the following year. Thus far in 2025, it's up even more -- 209% (returns as of Nov. 21). The company's trading platform is a hub for investing, trading, and betting. Whether it's buying stocks, crypto, or now making predictions, it's become a one-stop platform for a wide range of users.

The company has proven to be more than just a meme stock that's popular with retail investors. It has been generating some incredible growth, with phenomenal top- and bottom-line results. Robinhood recently posted its third-quarter earnings, and its revenue doubled to $1.3 billion for the period ending Sept. 30. Its Rule of 40 score over the trailing 12 months has been 131%, which is a key metric many growth investors focus on that factors in sales growth and earnings. It has been experiencing significant growth since expanding its prediction markets business, and that has the potential to be a growth catalyst for the foreseeable future as the company is even open to acquisitions to help expand that area of its operations quickly.

Today's Change

(

0.23

%) $

0.29

Current Price

$

128.49

Today, the stock's market cap is right around $100 billion, and it trades at a price-to-earnings (P/E) multiple of 48. It's an expensive stock to own, but with some exciting growth potential, I think a premium is justifiable for the business.

Palantir Technologies
Data analytics company Palantir Technologies has been another scorching-hot buy in recent years. Thus far in 2025, it's up around 115%, after skyrocketing 341% last year and 167% the year before that.

Retail hype is a big driving force with Palantir as its valuation is astounding, with a P/E multiple of around 380. A stock doesn't generate the type of returns Palantir does and trade at such a high valuation without strong support from retail investors. But that's not to say the company's results haven't been terrific; Palantir's sales rose by 63% in its most recent quarter (which ended on Sept. 30), totaling $1.2 billion. The company touts a Rule of 40 score of 114% as both its top and bottom lines have looked strong.

Today's Change

(

1.62

%) $

2.68

Current Price

$

168.45

But with a high share count, the company's valuation is rich on a per-share basis. A lot of artificial intelligence (AI) growth has been driving the stock's gains and the risk is if that slows down, that could be its undoing. In recent weeks the stock has been giving back some gains as investors grow concerned about valuations.

Given the risks, I wouldn't buy into Palantir's rally, as tempting as it might be, as there does appear to be considerable room for the stock to fall significantly in the event of a sell-off in the markets.

SoFi Technologies
Rounding out this list of high performers is SoFi Technologies. It's been rallying 78% this year after rising 55% last year and 116% back in 2023. One thing that it has in common with the other stocks listed here besides its impressive gains is that it's a popular company with retail investors.

SoFi has evolved over the years from student loan origination to offering a wide variety of financial products and services for its customers. Its focus on speed and convenience has made it a popular app for young people to own, not unlike Robinhood. Its member count has soared from 3.5 million in 2021 to more than 12.6 million people today. Its Rule of 40 score is 67%, as it has also been experiencing tremendous growth.

Today's Change

(

4.32

%) $

1.23

Current Price

$

29.72

It trades at a similar valuation to Robinhood, with its P/E ratio also around 50. Although it isn't a cheap stock to own, it can be a good one to hang on to for the long term, as it has proven to be a winner with retail investors.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

Investors have until January 5, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota and is captioned City of Pontiac Reestablished General Employees’ Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247.

Why is Inspire Being Sued For Securities Fraud?

Inspire develops and manufactures an implantable medical device for the treatment of sleep apnea. The latest version of the device is the Inspire V. The company announced FDA approval of Inspire V on August 2, 2024.

During the relevant period, Inspire repeatedly assured investors that it had taken all necessary steps to facilitate the launch of Inspire V and that it would launch the device as soon as sufficient inventory was available to meet supposedly high demand.

As alleged, in truth, Inspire failed to take basic steps to prepare clinicians and payors for the rollout, resulting in significant delays in adoption of the device. Moreover, the launch suffered from weak demand, as many customers already had excess inventory of the company’s older devices.

Why did Inspire’s Stock Drop?

On August 4, 2025, Inspire disclosed that the Inspire V launch was facing an “elongated timeframe” and as a result, it was reducing its 2025 earnings per share guidance by more than 80%. The company attributed the longer timeframe to a number of previously undisclosed factors including that many implanting centers “did not complete the training, contracting and onboarding required prior to the purchase and implant of Inspire V,” that certain “software updates for claims submissions and processing did not take effect until July 1, [2025]” which meant implanting centers could not bill for procedures until that date, and that demand for the Inspire V was poor because Inspire’s customers had a backlog of older versions of the company’s device.

On this news, the price of Inspire stock dropped $42.04 per share, or more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

What Can You Do?

If you invested in Inspire you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

November 29, 2025 6:17 AM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 29, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Jayud Global Logistics Ltd. (NASDAQ: JYD) between April 21, 2023 and April 30, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2026.

SO WHAT: If you purchased Jayud securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Jayud was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (3) Jayud's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price; and (4) as a result of the foregoing, defendants' positive statements about Jayud's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To join the Jayud class action, go to https://rosenlegal.com/submit-form/?case_id=48196 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276054

Snapchat, an app whose disappearing messages and silly face filters made chatting with loved ones more casual, is close to a milestone that few social media platforms achieve: reaching 1 billion monthly users.

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL, VFEX:CMCL) this week confirmed it will move forward with development of the Bilboes gold project following the release of a comprehensive feasibility study.

The company said the project contains approximately 2.3 million ounces of gold at a grade of over 2g/t, supporting a 10-year mine life with total production of 1.5 million ounces. Initial annual output is expected to reach 200,000 ounces.

Caledonia Mining said it plans to develop the project as a single-phase operation. The company noted this approach would generate stronger financial returns compared to a phased build. Peak capital expenditure is estimated at $484 million, with an additional $100 million allocated for financing-related items.

Using a gold price of $2,500 per ounce, the company reported a net present value of $580 million.

CEO Mark Learmonth joined the Proactive studio to talk us through the plans, and here, we take a closer look at what was said.

Proactive: Mark, good to have you along. Exciting news out from the company that you've made a decision to proceed on the Bilboes gold project. So, obviously, the results of the feasibility study have a lot to do with this. Take us through some of the key highlights that people should understand about the reasoning behind the decision.

Mark Learmonth: Yeah. We published an RNS this morning, and we've also published the full feasibility study — I think it is about 800 pages. Hopefully, the RNS gives a bit of an abbreviation, but it confirms that the project is a large high-grade project with just about 2.3 million ounces at over two grams a tonne, which is excellent for an open-pittable operation.

There's no change to the total production, which remains about 1.5 million ounces over ten years, although we've adjusted the phasing to bring more production forward, improving overall cash flow. In the first full year of production, we’re expecting about 200,000 ounces, which helps enormously.

CapEx has gone up — peak CapEx is now $484 million, plus another $100 million for things like interest. The increase isn't from scope changes but reflects inflation in input prices. However, that’s more than offset by the improved gold price.

Using a gold price of approximately $2,500, the NPV at 8% is just over $580 million. The ungeared IRR is over 32%. The all-in sustaining cost is $1,068 an ounce. So it's clearly a high-margin operation with a very quick payback — 1.7 years. At a higher gold price of $3,600, the NPV increases to $1.2 billion, and the IRR is 70% with a payback of just over a year.

Proactive: I want to pick up on something you talked about — the single-phased development approach you mentioned. Is it purely the economics that drove that decision?

Mark Learmonth: It is. We looked very closely at phased approaches to chop the CapEx into more manageable chunks. But the capital intensity of a smaller project increases — more dollars per ounce. That erodes the returns. So after reviewing and testing options, we decided to go with the big bang, single-phase approach.

Proactive: A lot of people ask about funding. Tell me a bit about the structure and how this is going to work.

Mark Learmonth: Given it’s a high-margin mine with a short payback, we believe senior non-recourse debt will provide most of the funding. The project has high debt capacity, but realistically, lenders may limit themselves to around 65–70% of the project value, which is still significant.

In addition, we’ve got the Blanket Mine, which will make a substantial contribution. As stated in the press release, we’ve entered into a three-year hedging arrangement locking in a minimum gold price of $3,500, which guarantees $200 million in cash flow from Blanket up to Caledonia.

That contributes substantially to the CapEx. And let me be clear: this is done with out-of-the-money put options — so no margin call risks, and we retain full upside participation if gold prices rise.

We’ll also consider hybrid instruments like streams or convertibles, but the goal is to minimise equity dilution. One of the reasons we've delivered strong returns over the past ten years is tight control over dilution. We aim to maintain that. I’m not saying there’ll be no equity dilution — but we’ll keep it tight.

Proactive: Okay. Timeline — what are you looking at?

Mark Learmonth: We’re starting the FEED phase — front-end engineering design — immediately. That takes about six months. Then we want to begin placing orders. There’s a big value uplift in starting this project sooner.

So we’re aiming to place orders for long-lead items in the second half of 2026. To do that, we’ll put short-term liquidity measures in place. Senior debt probably won’t flow until late 2026 or early 2027. Lenders move slowly, so we’re fast-tracking where we can.

We aim to begin construction in H2 2026, with initial production three years later — around late 2028. That’s an aggressive timetable and dependent on senior debt timing, but it’s our goal.

Proactive: Just a couple last questions from me. I imagine there's a lot of talk about this project in Zimbabwe. It's a boon for the economy, provides employment. A lot of eyes on it?

Mark Learmonth: You're right. It’ll be a marquee project in Zimbabwe. Gold production there has increased significantly due to high prices — this year’s output will be about 40 tonnes.

In its first year, Bilboes will add 6.5 tonnes — a significant contribution. It’ll also deliver substantial royalties, taxes, etc. We’re likely to make a fuller presentation early next year to wrap it all up.

But beyond the money, I think a project of this size helps Zimbabwe reclaim its position as a significant investment destination for gold. That’s long overdue.

Proactive: Last question — you mentioned a lot happening over the next three months to three years. What should people watch for?

Mark Learmonth: We’re close to year-end, so don’t expect much more in 2025. Key things to watch for in 2026 are progress on short-term liquidity measures, which will help us move faster.

Also, look for exploration updates — probably in February — at Blanket (both deep and shallow) and at Motapa, where we’re targeting sulphide material that would complement the Bilboes project. Expect that in early 2026.

Proactive: We'll keep an eye on all of that. Mark, thanks so much

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company’s fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its “inherent strength” and “the underlying momentum in our strategy.” The Company also stated on May 20, 2025, that it was seeing “normal stock levels” among its customers and that it was “seeing performance in the month to date as we would expect.”

As alleged, in truth, the Company’s North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered “in April through May” as customers “made efforts to return to more normal inventory levels[.]” The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

On November 17, 2025, James Hardie announced that Rachel Wilson had decided to step down from her role as CFO.

Click here for more information: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

Investors have until December 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.

Why Was MoonLake Sued for Securities Fraud?

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab (“SLK”), an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa (“HS”).

MoonLake told investors that its “strong clinical data,” including results from its Phase 2 MIRA trial, translate into “higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors.” The Company also stated that SLK’s Nanobody structure differed in beneficial ways from traditional monoclonal antibody treatments from its competitors.

As alleged, in truth, the Company’s clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug’s chances for regulatory approval and commercial viability.

The Stock Declines as the Truth Is Revealed

On September 28, 2025, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, with VELA-2 failing to meet its primary endpoint, calling into question the drug’s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 26, 2025, to $6.24 per share on September 29, 2025, the following trading day.

Click here for more information: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

What Can You Do?

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

Investors have until December 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410.

Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company’s Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company’s fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers “rely on Synopsys IP to minimize integration risk and speed time to market” and that it was seeing “strength in Europe and South Korea.” Synopsys also stated it was “continuing to develop and deploy[] AI into our products and the operations of our business.”

As alleged, in truth, the Company’s Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

The Stock Declines as the Truth Is Revealed

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its “IP business underperformed expectations.” The Company reported revenue for its Design IP segment of $425.9 million, a 7.7% decline year-over-year and net income of $242.5 million, a 43% year-over-year decline. The Company revealed that its Design IP customers require “more and more customization,” which “takes longer” and requires “more resources.” As a result, the Company stated it was having “an ongoing dialogue with our customers” regarding changing its business model. This news caused the price of Synopsys stock to fall $217.59 per share, or nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025.

Click here for more information: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

What Can You Do?

If you invested in Synopsys you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF) earlier this week confirmed that it had eliminated a key technical risk for its Phalaborwa project by adopting solvent extraction as its final separation method.

The company told investors that its previous approach - ion chromatography - had not achieved the required purity levels. By transitioning to solvent extraction, Rainbow was able to work with Australia’s Nuclear Science and Technology Organisation (ANSTO), which validated the ability to reach 99.5% purity for both Neodymium-Praseodymium and the SEG+ group.

Rainbow highlighted that its extraction circuits will be far smaller than traditional systems. It said the compact design, using just 75 mixer-settlers, supports low capital and operating costs.

CEO George Bennett joined the Proactive studio to talk about the project, this new milestone and rare earth market dynamics, and here, we take a closer look at what was said.

Proactive: George, good to speak with you. How does finalizing solvent extraction as the separation route materially de-risk Phalaborwa for investors?

George Bennett: Well, Rainbow always had this sort of risk discount to it because we were going down the path of ion chromatography for our final separation route, which has never been done commercially in rare earths before. But we looked at this as an alternative because we were very au fait with solvent extraction as a team, and also with continuous ion exchange.

So we thought ion chromatography could be a low capital-intensive method. We went down that path for a couple of years, but weren’t getting the purity and separation levels required. A year ago, we moved our pilot plant from Florida to South Africa and built our own lab, which significantly reduced costs and improved turnaround times on test results.

That allowed us to develop our flow sheet much quicker and at lower cost. We achieved a very high-grade leach solution and low impurity levels. That success allowed us to consider a smaller solvent extraction circuit.

Proactive: So how did ANSTO come into the picture?

George Bennett: We engaged ANSTO—Australia’s Nuclear Science and Technology Organisation—which is a global leader in solvent extraction for rare earths. They confirmed we could achieve 99.5% purity for both Neodymium-Praseodymium and the SEG+ group via two small solvent extraction circuits—just 75 mixer-settlers compared to up to 2,000 in some global projects.

This keeps us at the low end of capital and operating costs. It’s a significant de-risking step because we’re now using proven technology.

Proactive: George, yttrium prices have surged recently. How does this impact Phalaborwa’s EBITDA and what’s your view on sustainability of those prices?

George Bennett: Actually, we've seen even higher pricing in Europe—$220 to $320 per kilogram. That’s a 1,500% to 4,000% increase. Initially, we only expected value from Neodymium and Praseodymium, but now the SEG+ group adds significant value from dysprosium, terbium, yttrium, rhenium, and samarium.

Revenue from SEG+ could now reach around $160 million at 70% payability, versus $80 million previously. At EBITDA margins of 70–75%, that’s a major upside.

On sustainability, yttrium is critical for defense and aerospace. Since our announcement, a major aerospace and jet engine manufacturer has approached us for yttrium offtake at full pricing. With Chinese export restrictions likely due to military relevance, yttrium will remain a high-value rare earth.

Proactive: With ANSTO and METC Engineering onboard, what are the remaining technical milestones before the DFS is completed?

George Bennett: The key milestone—achieving separation and impurity thresholds—has now been met through solvent extraction. We’ll run a short pilot plant at ANSTO next year—seven days per circuit—to produce marketing samples.

From a technical standpoint, there's now nothing blocking the completion of the DFS, which we now expect in mid-2026. Previously, we couldn’t set a DFS timeline due to uncertainty in ion chromatography. That uncertainty is now removed.

Proactive: George, I hope you continue to keep us updated with your progress. Thank you for speaking with us.